These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 19447923)

  • 1. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
    Quittner AL; Modi AC; Wainwright C; Otto K; Kirihara J; Montgomery AB
    Chest; 2009 Jun; 135(6):1610-1618. PubMed ID: 19447923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
    J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis.
    Perrem L; Stanojevic S; Shaw M; Davis S; Retsch-Bogart G; Ratjen F
    J Cyst Fibros; 2020 May; 19(3):492-498. PubMed ID: 32139196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.
    Lang AB; Rüdeberg A; Schöni MH; Que JU; Fürer E; Schaad UB
    Pediatr Infect Dis J; 2004 Jun; 23(6):504-10. PubMed ID: 15194830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal trends in health-related quality of life in adults with cystic fibrosis.
    Dill EJ; Dawson R; Sellers DE; Robinson WM; Sawicki GS
    Chest; 2013 Sep; 144(3):981-989. PubMed ID: 23670667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
    Palser S; Smith S; Nash EF; Agarwal A; Smyth AR
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
    Flume PA; Clancy JP; Retsch-Bogart GZ; Tullis DE; Bresnik M; Derchak PA; Lewis SA; Ramsey BW
    J Cyst Fibros; 2016 Nov; 15(6):809-815. PubMed ID: 27233377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
    Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
    Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal assessment of exercise capacity and quality of life outcome measures in cystic fibrosis: A year-long prospective pilot study.
    Bhatia R; Kaye M; Roberti-Miller A
    J Eval Clin Pract; 2020 Feb; 26(1):236-241. PubMed ID: 30761692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
    Kosorok MR; Zeng L; West SE; Rock MJ; Splaingard ML; Laxova A; Green CG; Collins J; Farrell PM
    Pediatr Pulmonol; 2001 Oct; 32(4):277-87. PubMed ID: 11568988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
    Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
    J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.